|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:affects
|
viral load
C D4 cell count
|
|
gptkbp:approves
|
gptkb:1987
gptkb:FDA
|
|
gptkbp:associated_with
|
gptkb:Insurance_Company
gptkb:lipodystrophy
lactic acidosis
|
|
gptkbp:can_be_used_with
|
gptkb:abacavir
gptkb:lamivudine
gptkb:tenofovir
protease inhibitors
non-nucleoside reverse transcriptase inhibitors
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to zidovudine
|
|
gptkbp:developed_by
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discovered_by
|
gptkb:1980s
|
|
gptkbp:established
|
HIV reverse transcriptase
|
|
gptkbp:excretion
|
kidneys
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ZDV
|
|
gptkbp:interacts_with
|
gptkb:rifampin
gptkb:acetaminophen
valproic acid
ganciclovir
methadone
|
|
gptkbp:is_available_in
|
tablets
oral solution
injectable form
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_known_for
|
gptkb:zidovudine
|
|
gptkbp:is_monitored_by
|
liver function tests
blood cell counts
|
|
gptkbp:is_used_for
|
treatment of HIV
|
|
gptkbp:is_used_in
|
to reduce HIV transmission
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Retrovir
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_focus
|
combination therapies
drug resistance
HIV prevention strategies
long-term effects of treatment
HIV treatment regimens
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
headache
nausea
|
|
gptkbp:used_in
|
post-exposure prophylaxis
pre-exposure prophylaxis
|
|
gptkbp:bfsParent
|
gptkb:Davos_Airport
|
|
gptkbp:bfsLayer
|
7
|